• Press Release

Mount Sinai Launches Phase 1 U.S. Trial of NDV-HXP-S, an Egg-Based Investigational COVID-19 Vaccine, in Healthy Adults Previously Immunized Against COVID-19

  • New York, NY
  • (March 21, 2022)

A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.

This egg-based vaccine—called NDV-HXP-S—contains a recombinant Newcastle disease virus that expresses the spike protein of SARS-CoV-2, the virus that causes COVID-19. It does not contain any adjuvants nor any preservatives and may have the potential to provide additional immunity against COVID-19.

Mount Sinai’s COVID Clinical Trials Unit is looking for healthy, vaccinated individuals, aged 18-59, who received their last vaccine dose (primary series or booster) more than six months ago and have never tested positive for COVID-19 infection. Study participants will receive one of two dose levels of the NDV-HXP-S vaccine as an intranasal, intramuscular, or combined intranasal/intramuscular administration, or placebo. Additional study details are available at: https://clinicaltrials.gov/ct2/show/NCT05181709.

The vaccine that will be used in the study was developed by researchers at Icahn Mount Sinai. It has been or is currently being studied in clinical trials in Mexico, Thailand, Brazil, and Vietnam. Phase 1 results from those international trials are published in eClinicalMedicine (March 2022) medRxiv (September 2021) and (January 2022). Importantly, the physicians leading the U.S.-based phase 1 study at Mount Sinai—Sean Liu, MD, PhD, Assistant Professor of Medicine (Infectious Diseases) (Principal Investigator) and Judith Aberg, MD, Dr. George Baehr Professor of Clinical Medicine and Chief of the Division of Infectious Diseases (Co-Investigator)—are not the faculty inventors and have no financial interests related to this vaccine.

“Our microbiology team has a particular and impressive breadth of expertise in the understanding, evaluation, and development of RNA viruses and vaccines,” said Dr. Liu. “Now, our independent clinical research team is eager to do the rigorous, objective scientific work needed to evaluate this investigational vaccine. To that end, multiple safeguards have been implemented in order to protect the research objectivity and oversight of this clinical trial, so we are poised to begin and enrollment is currently open.”

Safeguards that have been put into place include use of an external institutional review board; appointment of clinical investigators without any financial interest with the vaccine or any reporting relationship to the faculty inventors; outsourcing verification of the main study endpoint (which measures anti-spike antibodies) to an expert at a separate institution; use of an independent data safety monitoring board comprising faculty members outside Mount Sinai; and use of an independent medical monitor.

If you are interested in potential participation in the trial, please call 212-824-7714 or email covidtrialsinfo@mountsinai.org to see if you qualify.

Disclosure: the vaccine used in this study was developed by faculty members at the Icahn School of Medicine at Mount Sinai. Mount Sinai is actively seeking to advance this vaccine to be available for commercial use.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.